Rhumbline Advisers Eloxx Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	SELL	$1.35 - $3.36 $40,181 - $100,007	-29,764 Closed	0 $0
Q1 2021 May 06, 2021	SELL	$3.02 - $4.54 $10,872 - $16,344	-3,600 Reduced 10.79%	29,764 $99,000
Q4 2020 Feb 10, 2021	BUY	$2.42 - $4.48 $13,431 - $24,864	5,550 Added 19.95%	33,364 $133,000
Q3 2020 Nov 12, 2020	SELL	$2.53 - $3.4 $15,167 - $20,383	-5,995 Reduced 17.73%	27,814 $73,000
Q2 2020 Aug 13, 2020	BUY	$1.56 - $3.65 $5,706 - $13,351	3,658 Added 12.13%	33,809 $102,000
Q1 2020 May 06, 2020	SELL	$1.96 - $7.96 $637 - $2,587	-325 Reduced 1.07%	30,151 $59,000
Q4 2019 Feb 05, 2020	BUY	$3.19 - $7.56 $925 - $2,192	290 Added 0.96%	30,476 $224,000
Q3 2019 Oct 23, 2019	BUY	$4.37 - $9.91 $3,461 - $7,848	792 Added 2.69%	30,186 $136,000
Q2 2019 Aug 14, 2019	BUY	$8.77 - $12.49 $15,075 - $21,470	1,719 Added 6.21%	29,394 $293,000
Q1 2019 May 01, 2019	SELL	$10.45 - $13.94 $9,269 - $12,364	-887 Reduced 3.11%	27,675 $323,000
Q4 2018 Jan 31, 2019	BUY	$10.43 - $17.39 $101,244 - $168,804	9,707 Added 51.48%	28,562 $343,000
Q3 2018 Nov 07, 2018	SELL	$11.95 - $19.63 $10,695 - $17,568	-895 Reduced 4.53%	18,855 $321,000
Q2 2018 Aug 06, 2018	BUY	$8.75 - $23.27 $172,812 - $459,582	19,750 New	19,750 $337,000

Ticker ELOX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,656,200
Description
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis p...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.